WHEREASLicense, Manufacturing and Supply Agreement • March 16th, 2006 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • California
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE, MANUFACTURING AND SUPPLY AGREEMENTLicense, Manufacturing and Supply Agreement • September 9th, 2013 • Ophthotech Corp. • Pharmaceutical preparations • California
PRODUCT, and NEKTAR AL agrees to undertake the manufacture and supply of the REAGENT specified under this AGREEMENT in accordance with the terms and conditions specified under this AGREEMENT.
LICENSE, MANUFACTURING AND SUPPLY AGREEMENTLicense, Manufacturing and Supply Agreement • April 29th, 2013 • Regado Biosciences Inc • Pharmaceutical preparations • California
This Agreement (“AGREEMENT”) is made and entered into December 22, 2006 (the “EFFECTIVE DATE”) by and between Nektar Therapeutics AL, Corporation, having its principal place of business at 490 Discovery Drive, Huntsville, AL 35806 (“NEKTAR AL”), and Regado Biosciences, Inc., having its principal place of business at 324 Blackwell Street, Suite 420, Durham, North Carolina 27701 (“COMPANY”). NEKTAR AL and COMPANY may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
LICENSE, MANUFACTURING AND SUPPLY AGREEMENTLicense, Manufacturing and Supply Agreement • December 11th, 2006 • Affymax Inc • Pharmaceutical preparations • California
License, Manufacturing And Supply AgreementLicense, Manufacturing and Supply Agreement • August 21st, 2007 • Adnexus Therapeutics, Inc. • California
This Agreement (“AGREEMENT”) is made and entered into August 5, 2005 (the “EFFECTIVE DATE”) by and between Nektar Therapeutics AL, Corporation, having its principal place of business at 490 Discovery Drive, Huntsville, AL 35806 (“NEKTAR AL”); and Compound Therapeutics, Inc. having its principal place of business at 100 Beaver Street, Waltham, MA 02453 (“COMPANY”). NEKTAR AL and COMPANY may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
AMENDMENT NO. 2 TO THE LICENSE, MANUFACTURING AND SUPPLY AGREEMENTLicense, Manufacturing and Supply Agreement • May 11th, 2015 • Ophthotech Corp. • Pharmaceutical preparations
This Amendment No. 2 to the License, Manufacturing and Supply Agreement (this “Amendment”) by and between Nektar Therapeutics, a Delaware corporation with offices at 455 Mission Bay Boulevard South, San Francisco, California 94158 (“Nektar”), successor by merger to Nektar Therapeutics AL, Corporation, an Alabama corporation, and Ophthotech Corporation, a Delaware corporation with offices at One Penn Plaza, Suite 1924, New York, NY 10119 (“Ophthotech”) is effective as of February 11th, 2015 (“Effective Date of Amendment No. 2”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the License, Manufacturing and Supply Agreement (the “Agreement”) made effective as of September 30, 2006 by and between Nektar and (OSI) Eyetech, Inc. (“OSI”), as amended by the Amendment No. 1 to the Agreement effective as of April 5, 2012 by and between Nektar and Ophthotech. Effective July 27, 2007, OSI assigned to Ophthotech all of OSI’s right, title an
